Open Outbreak

Oropouche fever

Also known as: Oropouche virus, OROV, Oropouche virus disease

Oropouche fever is an infection spread mainly by tiny biting flies called midges. Some mosquitoes may also transmit the virus. It occurs in South and Central America and the Caribbean, with a long history in the Amazon region. Symptoms usually begin four to eight days after an infected bite. They include sudden fever, headache, muscle and joint pain, and sometimes vomiting. Most people recover within a week, although recovery can take longer. Severe illness is uncommon, but inflammation around the brain, deaths, and infection passing from a pregnant person to a fetus have been reported. There is no specific antiviral treatment or vaccine in the WHO sources retrieved for this page. Preventing insect bites and detecting outbreaks are therefore important. WHO reported substantial geographic expansion during 2024, including infections outside previously recognized areas and cases in returning travellers. The latest WHO notice retrieved here is dated 2024-12-05; its figures and risk assessment should not be read as a verified account of conditions on 2026-11-22.

Key facts

TransmissionPrimarily bites from infected Culicoides paraensis midges; some mosquitoes may also transmit it. Maternal-to-fetal transmission was confirmed in 2024. Ordinary direct person-to-person spread was not documented in the retrieved WHO sources.
IncubationUsually 4–8 days; reported range 3–12 days, according to WHO's 2024 Cuba notice.
Case fatalityA reliable overall case-fatality rate is unknown from the retrieved sources. WHO reported 2 deaths among 11,634 confirmed cases in the Americas through 2024-11-25; this surveillance snapshot is not a general estimate of individual risk. Rates with and without treatment are unknown.
Reproduction numberunknown
VaccineNo vaccine was available according to the retrieved 2024 WHO notice; availability as of 2026-11-22 was not verified.
TreatmentNo specific antiviral treatment according to the retrieved WHO notice. Updated treatment guidance as of 2026-11-22 was not verified.
ReservoirForest-cycle hosts include primates, sloths and possibly birds. Humans can amplify transmission during outbreaks through biting insects.
Endemic regionsHistorically concentrated in the Amazon region, with recurring outbreaks in parts of South and Central America and the Caribbean. Endemic areas should be distinguished from places reporting imported infections.

Transmission

Oropouche virus reaches people mainly through bites from infected Culicoides paraensis midges, which are very small flies. Certain mosquitoes may also carry it. WHO describes a forest cycle involving primates, sloths and possibly birds, and an outbreak cycle in which insects carry the virus between humans. This does not mean people spread it through ordinary contact. WHO's earlier 2024 notice reported no evidence of direct human-to-human transmission. Its later notice documented transmission during pregnancy, from the pregnant person to the fetus. These are different routes and should not be confused. The incubation period—the time from an infected bite to symptoms—is usually four to eight days, with a reported range of three to twelve days. A reliable reproduction number was not provided by the retrieved sources.

Symptoms and severity

Illness usually starts suddenly, with fever, headache, chills, muscle or joint pain, and sometimes nausea or vomiting. Symptoms can resemble dengue, so symptoms alone may not identify the infection. WHO says most cases recover within seven days, although some people take weeks to recover. Severe disease is uncommon, but meningitis—inflammation of the protective tissues around the brain and spinal cord—can occur. A 2025 review also describes encephalitis, or inflammation of the brain itself. WHO reported two deaths among 11,634 confirmed infections in the Americas through 2024-11-25. That is a dated surveillance count, not a reliable universal fatality rate. Pregnancy deserves particular attention: WHO reported confirmed maternal-to-fetal transmission associated with fetal deaths and a congenital abnormality in Brazil in 2024. The size of these risks remains uncertain.

Treatment and vaccines

WHO's retrieved 2024 guidance states that there is no specific antiviral treatment and no vaccine for Oropouche virus disease. This page did not verify whether either status changed by 2026-11-22. An earlier research paper explored possible vaccine components, but research designs are not evidence that an approved vaccine is available. Because Oropouche symptoms resemble dengue and other infections, medical assessment matters rather than assuming that every fever after an insect bite is Oropouche. Most cases resolve within a week, but prolonged recovery and rare neurological complications are reasons not to dismiss persistent illness. The retrieved sources do not provide a detailed medicine regimen or establish how treatment changes the risk of death. Prevention therefore centres on reducing exposure to biting insects and public-health measures that monitor and control those insects.

Where it occurs

Oropouche has historically been associated with the Amazon region, but its range is wider than that label suggests. WHO describes periodic outbreaks in rural and urban communities in Brazil, Bolivia, Colombia, Ecuador, French Guiana, Panama, Peru, and Trinidad and Tobago. Cuba reported its first detected outbreak in 2024. By 2024-11-25, Brazil had reported cases in 22 of its 27 states, including locally acquired infections in 15 states outside the Amazon region. WHO also reported cases in travellers returning to Canada, the United States and European countries. Imported cases do not, by themselves, show that local insects are transmitting the virus at the destination. The geographic picture given here comes from dated sources, mainly from 2024, and is not a verified map of active transmission on 2026-11-22.

Recent history

Open Outbreak's supplied archive contains four Oropouche events: Peru in 2016, French Guiana in 2020, Cuba in 2024, and a regional Americas event in 2024. This is a count of archived events, not all outbreaks worldwide. A 2018 review described more than 30 epidemics over the preceding six decades. WHO's notice dated 2024-12-05 updated the regional event, reporting 11,634 confirmed cases and two deaths through 2024-11-25. It also highlighted geographic expansion and confirmed maternal-to-fetal transmission. At that time, WHO assessed public-health risk as high regionally and low globally. Those assessments are historical, not confirmed current ratings. The archive's regional case figure does not match the date of its listed notice, so this page uses the dated WHO update for that count. No newer WHO notice was returned in this session.

What to watch

The clearest warning signals are locally acquired infections in new regions, sustained increases in confirmed cases, and evidence that additional insect species can transmit the virus. Imported infections should be tracked separately from local spread. More deaths, neurological complications, or confirmed infections during pregnancy would also deserve close attention, especially when studies can measure risk rather than simply describe individual cases. Evidence of a new direct human-to-human route would change the transmission picture; the retrieved sources do not establish such routine spread. WHO called for stronger disease surveillance and monitoring of biting insects in its 2024 regional assessment. Vaccine development and eventual availability are worth tracking, but the sources here establish no vaccine supply programme. Likewise, they identify no specific antiviral whose resistance could currently be monitored; insect-control effectiveness is a more immediate surveillance concern.

Updated